SCHEMBL2809862

SCHEMBL2809862

COc1ccc(CN2CCc3nn(C)c4nc(NCCN5CCOCC5)nc2c34)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 2/20 0.47
MTOR P42345 2/20 0.47
MAPK1 P28482 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
HPGD P15428 2/20 0.43
MAPT P10636 1/20 0.43
EGFR P00533 1/20 0.43
PDE5A O76074 2/20 0.43
RAB9A P51151 2/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
BACE1 P56817 2/20 0.41
PIM1 P11309 1/20 0.41
LMNA P02545 3/20 0.41
TSHR P16473 2/20 0.40
MEN1 O00255 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.40
PKM P14618 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2812306 0.89 LMNA (0.46) PIK3CAMTORMAPK1SMN1; SMN2HPGD
SCHEMBL2814487 0.87 BCDIN3D (0.40) MAPK1SMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL538654 0.85 PIK3CA (0.46) PIK3CAMTORMAPK1SMN1; SMN2HPGD
SCHEMBL13131652 0.85 SHMT2 (0.48) MAPTKDM4EMEN1KMT2A
SCHEMBL2809950 0.84 BCDIN3D (0.38) MAPK1SMN1; SMN2MAPTLMNATSHR
SCHEMBL2810448 0.83 BCDIN3D (0.42) MAPK1SMN1; SMN2MAPTLMNATSHR
SCHEMBL2809534 0.83 MAPT (0.40) SMN1; SMN2MAPTEGFRKDM4EALDH1A1
SCHEMBL2812793 0.83 HRH1 (0.47) MAPTBACE1MEN1KMT2ANPSR1
SCHEMBL2809426 0.82 HRH1 (0.39) MAPTKDM4EALDH1A1KMT2A
SCHEMBL2812150 0.82 SMN1; SMN2 (0.39) MAPK1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS DPYD, TYMP, TP53 PIK3CA 74/4885MTOR 351/4885MAPK1 1997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.